New Cyprus NHS law paves the way to improve patients' access to innovative medicines

3 July 2017

The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) has welcomed the vote on the National Health Service (NHS) bill by the House of Representatives Plenum.

This is an important moment for the Republic of Cyprus and its citizens. The law’s approval paves the way to start implementing a system that needs to improve the current situation, eradicating inequalities that exist today between the private and public sector.

One of the most important issues the NHS will have to deal with is ensuring patients’ access to medicines, which unfortunately is a black spot in the healthcare available in Cyprus today, says the KEFEA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK